|
|
Adcock - offer by Natco Pharma
Adcock Ingram shareholders were referred to the Circular and the announcement of the results of the General Meeting released on SENS on Friday, 10 October 2025, wherein it was confirmed that the resolution necessary to approve the Scheme, was approved by the requisite majority of Adcock Ingram shareholders present (in person or represented by proxy) at the General Meeting held on Thursday, 9 October 2025.
Adcock Ingram confirmed that all of the Scheme Conditions Precedent, as outlined in the Circular, have now been fulfilled or waived (where permitted), as the case may be, and that the Scheme has accordingly become unconditional with effect from Friday 24 October 2025. Consequently, Adcock Ingram will proceed with the implementation of the Scheme.
|
|
Click here for original article
|
| |
| |
| Click here for full news archive for this company |
|
| Closing price data source: JSE Ltd. All other statistics calculated by ProfileData. |
| |
|
|
